Skip to main content

Table 3 Comparison of the baseline characteristics of ADA-positive and ADA-negative SLE patients

From: First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

  ADA positive (n = 25) ADA negative (n = 41) P value*
Patient characteristics
 Age (years, median (IQR)) 34.0 (25.9–40.8) 44.3 (32.7–56.3) 0.002
 Sex (Females, n, %) 27 (87.1) 33 (94.2) 0.66
 Disease duration (years, median (IQR)) 4.14 (1.18–10.08) 9.19 (5.71–16.93) 0.0097
Disease activity
 SLEDAI-2 K (median (IQR)) 14.0 (10.0–18.5) 8.0 (6.0–14.0) 0.017
Laboratory data
 Total leukocytes (N cells/mm3 median (IQR)) 6.3 (4.1–8.1) 7.1 (4.7–9.5) 0.53
 Total lymphocytes (N cells/mm3 median (IQR)) 0.98 (0.54–1.47) 0.85 (0.5–1.52) 0.74
 CD19 + cells (%, median (IQR)) 8.0 (5.25–14.5) 6.0 (2.5–11.5) 0.17
 CD19 + cells (N × 10^9/L, median (IQR)) 0.065 (0.03–0.15) 0.05 (0.03–0.085) 0.21
Treatments
 Concomitant CS pulses, % (n) 60.0 (15) 53.6 (22) 0.61
 Concomitant cyclophosphamide, % (n) 56.0 (14) 53.6 (22) 0.85
 Cumulative dose of concomitant cyclophosphamide (mg, (median (IQR)) 1200 (950–1600) 1000 (1000–1600) 0.81
 Previous cyclophosphamide, % (n) 60.0 (15) 60.0 (25) 0.93
 Cumulative dose of previous cyclophosphamide (mg, median (IQR)) 6700 (4500–10000) 6000 (3000–9150) 0.58
 Corticosteroids at baseline, % (n) 92 (23) 92.6 (38) 0.91
 Total corticosteroid dose at baseline (mg, median (IQR)) 12.5 (10–17.5) 15.0 (7.5–20.0) 0.73
 Antimalarial treatment at baseline, % (n) 36.0 (9) 43.9 (18) 0.53
 DMARDs at baseline (AZA, MMF, MTX), n 0/4/1 6/5/2 n/a
Rituximab treatment (from baseline)
 Schedule of RTX (n, 375 mg/m2 × 4, 1 g × 2, 500 mg × 2)) 14/10/1 24/14/3 1.00
 Cumulative dose of RTX at first course (mg, median (IQR)) 2100 (2000–2650) 2400 (2000–2800) 0.33
  1. IQR Interquartile range, SLEDAI-2 K SLE Disease Activity Index-2000, CD19 Cluster of differentiation 19, RTX Rituximab, n/a Not applicable, DMARDs Disease-modifying anti-rheumatic drugs, AZA Azathioprine, MMF Mycophenolate mofetil, MTX Methotrexate, CS Corticosteroids
  2. *Mann–Whitney test